What we’ve done.

 
  1. Zhao J, Cheng C. Artificial Intelligence, in Understanding the Principles and Practice of Legal Oncology, Tony Quang et al., eds. (2020).

  2. Edwards S, Cheng C, et al. The Case for Methodological Pluralism in Medical Science, 20 Am. J. Bioethics 39 (2020).

  3. Harvey HB, Gowda V. How the FDA Regulates AI. Acad Radiol. 2020;27(1):58-61.

  4. Harrington SG, Harvey HB. Quality Improvement and Reimbursements: An Opportunity to Address Health Disparities in Radiology. J Am Coll Radiol. 2019;16(4 Pt B):635-637. 

  5. Daye D, Carrodeguas E, Glover M 4th, Guerrier CE, Harvey HB, Flores EJ. Impact of Delayed Time to Advanced Imaging on Missed Appointments Across Different Demographic and Socioeconomic Factors. J Am Coll Radiol. 2018;15(5):713-720.

  6. Wang B, Rosenthal DI, Xu C, Harvey HB, et al. The Effect of Computer-Assisted Reporting on Interreader Variability of Lumbar Spine MRI Degenerative Findings: Five Readers With 30 Disc Levels. J Am Coll Radiol. 2018;15(11):1613-1619.

  7. Harvey HB, Sotardi ST. Carlson's Law and the Power of Frontline Innovation. J Am Coll Radiol. 2018;15(1 Pt A):86-87.

  8. Cheng G, Cyr S, Roscetti J. Time to GAIN: Are Your FDA Marketing Exclusivities Eligible for Extension?, Biopharm Intl (2018).

  9. Harvey HB, Liu C, Ai J, et al. Predicting No-Shows in Radiology Using Regression Modeling of Data Available in the Electronic Medical Record. J Am Coll Radiol. 2017;14(10):1303-1309.

  10. Alkasab TK, Bizzo BC, Berland LL, Nair S, Pandharipande PV, Harvey HB. Creation of an Open Framework for Point-of-Care Computer-Assisted Reporting and Decision Support Tools for Radiologists. J Am Coll Radiol. 2017;14(9):1184-1189.

  11. Cheng G. FDA Guidance on Whether to Submit an ANDA or 505(b)(2) Application, IP FDA Blog (Oct. 14, 2017).

  12. Cheng G. FDA Guidance on Formal Meetings Between FDA and ANDA Applicants of Complex Products, IP FDA Blog (Oct. 3, 2017).

  13. Cheng G. The Aesthetics of Copyright Adjudication, 19 UCLA Ent. L. Rev. 113 (2012).